Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Appointment of New Executive Officer
On August 2, 2021, G1 Therapeutics, Inc. (the "Company") announced the
appointment of Andrew Perry as Chief Commercial Officer. Mr. Perry joins the
Company from ViiV Healthcare NA, a joint venture majority-owned by
GlaxoSmithKline, where he served as Vice President, US Marketing. Mr. Perry
brings nearly 25 years of leadership experience in product commercialization and
managed markets to the Company, having led multiple successful product launches
and growing brands.
Departure of Executive Officer
On July 27, 2021, the Company and Soma Gupta, Chief Commercial Officer, mutually
agreed to separate. Ms. Gupta left the Company for personal and professional
reasons.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release dated August 2, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses